Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: A reassessment in vitro and in vivo

Psychopharmacology

Volumn 220, Issue 1, 2012, Pages 225-241

  Humbert Claude, Marie ^a   Davenas, Elisabeth ^a   Gbahou, Florence ^a   Vincent, Ludwig ^a   Arrang, Jean Michel ^a  

^a CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

Author keywords

H 1 receptor; H 2 receptor; H 3 receptor; Human histamine receptors; Inverse agonist; Partial agonist; Rat brain

Indexed keywords

CLOZAPINE; CLOZAPINE N OXIDE; CYCLIC AMP; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE H3 RECEPTOR; HISTAMINE H4 RECEPTOR; HISTAMINE RECEPTOR; NORCLOZAPINE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOACCUMULATION; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; SPECIES COMPARISON; UPREGULATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; DRUG INVERSE AGONISM; HISTAMINE AGONISTS; HUMANS; MALE; RATS; RATS, WISTAR; RECEPTORS, HISTAMINE; RETROSPECTIVE STUDIES; UP-REGULATION;

EID: 84858442357     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2471-5     Document Type: Article

References (115)

1. 2 receptor. J Neurochem 71:799-807 (Pubitemid 28480429)
2. 3 receptor in rat brain cortex. Arch Pharm (Weinheim) 329:413-416 (Pubitemid 26334436)
3. Arrang JM (2007) Histamine and schizophrenia. Int Rev Neurobiol 78:247-287
4. 3 receptor. Trends Pharmacol Sci 28:350-357 (Pubitemid 47016682)
5. 1 receptor antagonists. Eur J Pharmacol 387:R5-R7 (Pubitemid 30035384)
6. 1 receptor agonists. J Pharmacol Exp Ther 322:172-179 (Pubitemid 46956351)
7. Baldessarini RJ, Frankenburg FR (1991) Clozapine. A novel antipsy-chotic agent. N Engl J Med 324:746-754
8. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM (1993) Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharma-cology 9:117-124 (Pubitemid 23275837)
9. 3 antagonist. Br J Pharmacol 143:649-661 (Pubitemid 39524283)
10. Bell R, McLaren A, Galanos J, Copolov D (1998) The clinical use of plasma clozapine levels. Aust N Z J Psychiatry 32:567-574 (Pubitemid 28393520)
11. 4 receptor. Br J Pharmacol 140:1117-1127 (Pubitemid 37475978)
12. 3-receptor inverse agonists. Psycho-pharmacology (Berl) 210:591-604
13. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96 (Pubitemid 26053226)
14. 3 receptor antagonists reach out for the clinic. Drug Discov Today 10:1613-1627 (Pubitemid 41817610)
15. v mice. Brain Res 968:162-166 (Pubitemid 36315685)
16. i) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
17. 4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol 157:55-63
18. 2-receptors differs in intact cells and cell-free preparations. Nature 287:548-551 (Pubitemid 11232855)
19. Davis CN, Bradley SR, Schiffer HH, Friberg M, Koch K, Tolf BR, Bonhaus DW, Lameh J (2009) Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands. BMC Pharmacol 9:14
20. 4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci 26:462-469 (Pubitemid 41207878)
21. 3 receptor isoforms with different brain expression and signaling properties. Mol Pharmacol 59:1-8 (Pubitemid 32043078)
22. 3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol Interv 6(77-88):59
23. Ferno J, Vik-Mo AO, Jassim G, Havik B, Berge K, Skrede S, Gudbrandsen OA, Waage J, Lunder N, Mork S, Berge RK, Jorgensen HA, Steen VM (2009) Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl) 203:73-84
24. 1 receptor inverse agonist, binds preferentially to a G protein-coupled form of the receptor and sequesters G protein. J Biol Chem 279:34431-34439 (Pubitemid 39318069)
25. Flanagan RJ, Dunk L (2008) Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 23(Suppl 1):27-41 (Pubitemid 351166610)
26. 3 receptor antagonist. J Pharmacol Exp Ther 313:176-190 (Pubitemid 40411341)
27. 2 receptor with low basal activity, is resistant to upregulation upon antagonist exposure. Pharmacogenomics J 1:78-83 (Pubitemid 33757987)
28. 3 receptors in vitro and in vivo. Proc Natl Acad Sci USA 100:11086-11091 (Pubitemid 37140156)
29. 4 receptors: structure-activity relationships of histamine derivatives. Br J Pharmacol 147:744-754
30. Gerson SL, Arce C, Meltzer HY (1994) N-Desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. Br J Haema-tol 86:555-561 (Pubitemid 24199044)
31. Girgis RR, Javitch JA, Lieberman JA (2008) Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry 13:918-929
32. Goethe JW, Szarek BL, Caley CF, Woolley SB (2007) Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review. J Clin Psychiatry 68:22-28 (Pubitemid 46220120)
33. 2 receptor in brain. Nature 269:163-165
34. Green JP, Johnson CL, Weinstein H, Maayani S (1977) Antagonism of histamine-activated adenylate cyclase in brain by D-lysergic acid diethylamide. Proc Natl Acad Sci USA 74:5697-5701
35. Haas H, Panula P (2003) The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 4:121-130 (Pubitemid 37271382)
36. Haas HL, Sergeeva OA, Selbach O (2008) Histamine in the nervous system. Physiol Rev 88:1183-1241
37. Haddad PM, Sharma SG (2007) Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21:911-936 (Pubitemid 47557106)
38. 3 receptor antagonists/inverse agonists. Expert Opin Investig Drugs 14:223-241 (Pubitemid 40520963)
39. 3 receptor ligands and neurological disease. Expert Opin Investig Drugs 13:1237-1248 (Pubitemid 39359655)
40. Hegstrand LR, Kanof PD, Greengard P (1976) Histamine-sensitive adenylate cyclase in mammalian brain. Nature 260:163-165
41. 1 receptor-deficient mice. Epilepsia 45:309-313 (Pubitemid 38489983)
42. 4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 305:1212-1221 (Pubitemid 36618001)
43. Hong CJ, Lin CH, Yu YW, Chang SC, Wang SY, Tsai SJ (2002) Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment. Psychiatr Genet 12:169-171 (Pubitemid 35316205)
44. 2 receptor gene variants: lack of association with schizophrenia. Mol Psychiatry 5:159-164 (Pubitemid 30229430)
45. Iverson S, Kautiainen A, Ip J, Uetrecht JP (2010) Effect of clozapine on neutrophil kinetics in rabbits. Chem Res Toxicol 23:1184-1191
46. Kamei C (2001) Involvement of central histamine in amygdaloid kindled seizures in rats. Behav Brain Res 124:243-250 (Pubitemid 32964642)
47. Kaminsky R, Moriarty TM, Bodine J, Wolf DE, Davidson M (1990) Effect of famotidine on deficit symptoms of schizophrenia. Lancet 335:1351-1352 (Pubitemid 20186429)
48. Kanof PD, Greengard P (1978) Brain histamine receptors as targets for antidepressant drugs. Nature 272:329-333 (Pubitemid 8308076)
49. 3 receptors. Psychopharmacology (Berl) 116:464-468 (Pubitemid 24374248)
50. 1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 104:3456-3459 (Pubitemid 46364180)
51. 1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharma-cology 28:519-526
52. Kumar R, Palit G, Dhawan BN (2003) Comparative behavioural effects of typical and atypical antipsychotic drugs in rhesus monkey. Eur J Pharmacol 462:133-138 (Pubitemid 36183744)
53. Lameh J, Burstein ES, Taylor E, Weiner DM, Vanover KE, Bonhaus DW (2007) Pharmacology of N-desmethylclozapine. Pharmacol Ther 115:223-231 (Pubitemid 47042913)
54. 2 antagonist ketanserin. Psychopharmacology (Berl) 212:551-558
55. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41
56. 1 receptor. II. Stable expression in Chinese hamster ovary cells reveals the interaction with three major signal transduction pathways. J Neurochem 62:519-527 (Pubitemid 24041318)
57. 3 receptors. J Pharmacol Exp Ther 271:452-459
58. Lin JS (2000) Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 4:471-503
59. 4) expressed in bone marrow. Mol Pharmacol 59:420-426 (Pubitemid 32179918)
60. 4 receptors reveals substantial pharmacological species variation. J Pharmacol Exp Ther 299:121-130 (Pubitemid 32905126)
61. 3 receptor. Mol Pharmacol 55:1101-1107 (Pubitemid 29252378)
62. 3 receptor reveals distinct species pharmacological profiles. J Pharmacol Exp Ther 293:771-778 (Pubitemid 30417841)
63. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
64. Mancama D, Arranz MJ, Munro J, Makoff A, Kerwin R (2000) The histamine 1 and histamine 2 receptor genes-candidates for schizophrenia and clozapine drug response. Genescreen 1:29-34
65. Mancama D, Arranz MJ, Munro J, Osborne S, Makoff A, Collier D, Kerwin R (2002) Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. Neurosci Lett 333:207-211 (Pubitemid 35335778)
66. Masaki T, Yoshimatsu H (2009) Molecular mechanisms of neuronal histamine and its receptors in obesity. Curr Mol Pharmacol 2:249-252
67. 1 receptor in the regulation of feeding rhythm and obesity. Diabetes 53:2250-2260 (Pubitemid 39145578)
68. Mendoza MC, Lindenmayer JP (2009) N-Desmethylclozapine: is there evidence for its antipsychotic potential? Clin Neuropharmacol 32:154-157
69. Morisset S, Sahm UG, Traiffort E, Tardivel-Lacombe J, Arrang JM, Schwartz JC (1999) Atypical neuroleptics enhance histamine turnover in brain via 5-hydroxytryptamine2A receptor blockade. J Pharmacol Exp Ther 288:590-596 (Pubitemid 29119669)
70. 3 receptors regulates histamine neurons in brain. Nature 408:860-864 (Pubitemid 32016096)
71. Morse KL, Behan J, Laz TM, West RE Jr, Greenfeder SA, Anthes JC, Umland S, Wan Y, Hipkin RW, Gonsiorek W, Shin N, Gustafson EL, Qiao X, Wang S, Hedrick JA, Greene J, Bayne M, Monsma FJ Jr (2001) Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther 296:1058-1066 (Pubitemid 32187382)
72. 3- receptor antagonist/inverse agonist, modulates methamphetamine-induced sensitization in mice. Eur J Neurosci 33:1197-1204
73. Nasrallah HA (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13:27-35 (Pubitemid 350275185)
74. Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S (2007) Evaluation of N-desmethylclozapine as a potential antipsychotic -preclinical studies. Neuropsychopharmacology 32:1540-1549 (Pubitemid 46920156)
75. Newcomer JW (2007) Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68(Suppl 1):20-27
76. Nooijen PM, Carvalho F, Flanagan RJ (2010) Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum Psychopharmacol 26:112-119
77. Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S (2000) Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 275:36781-36786 (Pubitemid 32002087)
78. Oyewumi LK, Vollick D, Merskey H, Plumb C (1994) Famotidine as an adjunct treatment of resistant schizophrenia. J Psychiatry Neurosci 19:145-150 (Pubitemid 24131865)
79. Parker RB, Waud DR (1971) Pharmacological estimation of drug-receptor dissociation constants. Statistical evaluation. I. Agonists. J Pharmacol Exp Ther 177:1-12
80. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 25:618-625 (Pubitemid 39458167)
81. Pei G, Samama P, Lohse M, Wang M, Codina J, Lefkowitz RJ (1994) A constitutively active mutant beta 2-adrenergic receptor is constitutively desensitized and phosphorylated. Proc Natl Acad Sci USA 91:2699-2702 (Pubitemid 24139415)
82. 4 histamine receptors mediate cell cycle arrest in growth factor-induced murine and human hematopoietic progenitor cells. PLoS One 4:e6504
83. 3 receptor and its gene transcripts in rat brain. Neuroscience 114:173-193 (Pubitemid 35247499)
84. 3H- mepyramine may predict sedative properties of psychotropic drugs. Eur J Pharmacol 60:391-392 (Pubitemid 10168550)
85. Reynolds GP, Kirk SL (2010) Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 125:169-179
86. Richelson E, Nelson A (1984) Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 103:197-204 (Pubitemid 14028974)
87. Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29-39
88. 1 receptor involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of clozapine. Pharmacol Biochem Behav 86:686-692 (Pubitemid 46829322)
89. Rosse RB, Kendrick K, Fay-McCarthy M, Prell GD, Rosenberg P, Tsui LC, Wyatt RJ, Deutsch SI (1996) An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmaco-therapy in schizophrenia: preliminary evidence for treatment efficacy. Clin Neuropharmacol 19:341-348 (Pubitemid 26250117)
90. Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359 (Pubitemid 38499762)
91. 125I]iodinated probes. Proc Natl Acad Sci USA 87:1658-1662
92. Sakata T, Yoshimatsu H, Kurokawa M (1997) Hypothalamic neuronal histamine: implications of its homeostatic control of energy metabolism. Nutrition 13:403-411 (Pubitemid 27282131)
93. 1-antagonists. Prog Neurobiol 52:145-157 (Pubitemid 27242704)
94. 3 receptors is not shared by its two major metabolites and by structurally related and unrelated atypical neuroleptics. Naunyn Schmiedebergs Arch Pharmacol 353:290-294 (Pubitemid 26092045)
95. Schotte A, Janssen PF, Megens AA, Leysen JE (1993) Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 631:191-202 (Pubitemid 24009988)
96. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57-73 (Pubitemid 26112775)
97. Seeman P (1992) Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7:261-284
98. 2 receptors. Proc Natl Acad Sci USA 93:6802-6807 (Pubitemid 26230391)
99. 4 receptors in the central nervous system of human and rat. Brain Res 1250:41-48
100. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, Brandish PE, Pettibone DJ, Scolnick EM, Conn PJ (2003) N-Desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100:13674-13679 (Pubitemid 37444798)
101. 4 receptor in zymosan-induced neutrophil recruitment from the bone marrow: comparison with carrageenan. J Pharmacol Exp Ther 310:272-280 (Pubitemid 38812721)
102. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ (2008) World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsy-chotics in the treatment of schizophrenia. Schizophr Res 100:20-38
103. Theisen FM, Haberhausen M, Firnges MA, Gregory P, Reinders JH, Remschmidt H, Hebebrand J, Antel J (2007) No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J 7:275-281 (Pubitemid 47202490)
104. 2 receptor activity regulates serotonin release in the substantia nigra. J Neurochem 107:745-755
105. 3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J Pharmacol Sci 101:12-18 (Pubitemid 43765331)
106. Tuomisto L, Lozeva V, Valjakka A, Lecklin A (2001) Modifying effects of histamine on circadian rhythms and neuronal excitability. Behav Brain Res 124:129-135 (Pubitemid 32964630)
107. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S (2007) Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci 80:1635-1640 (Pubitemid 46412363)
108. Weigmann H, Hartter S, Fischer V, Dahmen N, Hiemke C (1999) Distribution of clozapine and desmethylclozapine between blood and brain in rats. Eur Neuropsychopharmacol 9:253-256 (Pubitemid 29114932)
109. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, Vanover KE, Olsson R, Jayathilake K, Lee M, Levey AI, Hacksell U, Burstein ES, Davis RE, Brann MR (2004) The role of M1 muscarinic receptor agonism of N-desmethylclo-zapine in the unique clinical effects of clozapine. Psychophar-macology (Berl) 177:207-216 (Pubitemid 40109932)
110. 3 receptor. Neuropharmacology 42:929-940 (Pubitemid 34632680)
111. Wong J, Delva N (2007) Clozapine-induced seizures: recognition and treatment. Can J Psychiatry 52:457-463 (Pubitemid 47195851)
112. Yokoyama H (2001) The role of central histaminergic neuron system as an anticonvulsive mechanism in developing brain. Brain Dev 23:542-547 (Pubitemid 32999123)
113. 3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc Natl Acad Sci USA 103:13866-13871 (Pubitemid 44413999)
114. 3 receptor in various orexigenic pathways. Eur J Pharmacol 579:229-232
115. Zhu Y, Michalovich D, Wu H, Tan KB, Dytko GM, Mannan IJ, Boyce R, Alston J, Tierney LA, Li X, Herrity NC, Vawter L, Sarau HM, Ames RS, Davenport CM, Hieble JP, Wilson S, Bergsma DJ, Fitzgerald LR (2001) Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol 59:434-441 (Pubitemid 32179920)